D’Amico, A.V. (2002) Combined-Modality Staging in Predicting Prostate-Specific Antigen Outcome after Definitive Local Therapy for Men with Clinically Localized Prostate Cancer. In: Prostate Cancer: Principles & Practice, Lippincott Williams & Wilkins, Philadelphia, PA, 254-268.

has been cited by the following article:

• TITLE: Expending the Paradigm: Active Surveillance for Intermediate Risk Prostate Cancer

  AUTHORS: Mohamed Jalloh, Mamadou Tieoule Traore, Thierno Amadou Diallo, Issa Labou, Lamine Niang, Serigne Magueye Gueye

  KEYWORDS: Prostate Cancer, Active Surveillance, Intermediate Risk

  JOURNAL NAME: Open Journal of Urology, Vol.8 No.8, August 30, 2018

  ABSTRACT: Prostate cancer is the leading male cancer worldwide. There remains a controversy as to which patients have indolent disease and which patients present an aggressive disease needing treatment with intent to cure. Because of quality of life impairment associated with treatment by radiation or surgery, active surveillance (AS) is a valid management option to avoid or differ aggressive treatment. Traditionally, AS was reserved for men with low risk prostate cancer, however intermediate risk patients are more and more found in AS cohorts. The aim of this review is to describe the place of AS in intermediate risk patients and the perspectives offered by such a treatment modality.